Postoperative analgesic efficacy and safety of imrecoxib versus celecoxib in hip osteoarthritis patients undergoing total hip arthroplasty: a multi-center, randomized, controlled, non-inferiority study

被引:0
作者
Kai Zhang
Xiaoyan Miao
Liqiang Jiang
Shubei Cui
Zhenwu Liu
Zhiyun Wang
机构
[1] Handan Central Hospital,Department of Orthopedics
[2] Affiliated Hospital of Hebei Engineering University,Department of General Surgery
来源
Inflammopharmacology | 2023年 / 31卷
关键词
Total hip arthroplasty; Imrecoxib; Celecoxib; Postoperative analgesia; Safety;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1813 / 1822
页数:9
相关论文
共 83 条
  • [1] Ahmadi M(2022)Non-steroidal anti-inflammatory drugs: recent advances in the use of synthetic COX-2 inhibitors RSC Med Chem 13 471-496
  • [2] Bekeschus S(2021)PROSPECT guideline for total hip arthroplasty: a systematic review and procedure-specific postoperative pain management recommendations Anaesthesia 76 1082-1097
  • [3] Weltmann KD(2016)Hip osteoarthritis BMJ 354 i3405-e143
  • [4] von Woedtke T(2017)Essential elements of multimodal analgesia in enhanced recovery after surgery (ERAS) guidelines Anesthesiol Clin 35 e115-931
  • [5] Wende K(2004)Imrecoxib: a novel and selective cyclooxygenase 2 inhibitor with anti-inflammatory effect Acta Pharmacol Sin 25 927-1671
  • [6] Anger M(2012)Single dose oral celecoxib for acute postoperative pain in adults Cochrane Database Syst Rev 3 CD004233-2992
  • [7] Aresti N(2018)Hip replacement Lancet 392 1662-761
  • [8] Kassam J(2022)Global, regional, and national burdens of hip osteoarthritis from 1990 to 2019: estimates from the 2019 Global Burden of Disease Study Arthritis Res Ther 24 8-1551
  • [9] Nicholas N(2017)The efficacy of Imrecoxib and celecoxib in axial spondyloarthritis and their influence on serum Dickopff-Related protein 1 (DKK-1) levels Med Sci Monit 23 2985-881
  • [10] Achan P(2019)Relative efficacy of different exercises for pain, function, performance and quality of life in knee and hip osteoarthritis: systematic review and network meta-analysis Sports Med 49 743-2807